Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Cota Chief Medical Officer to Present at the HealthXL Global Gathering 2018


NEW YORK, Jan. 17, 2018 /PRNewswire/ -- Cota Inc., a real-world data and analytics company bridging precision medicine to population health, today announced its chief medical officer, Andrew Norden, M.D., will speak at the HealthXL Global Gathering in Pittsburgh, Pennsylvania on February 8, 2018. The event, which will take place at the National Robotics Engineering Center, showcases leaders and innovators from the world's most disruptive technology companies in healthcare.

Cota Logo.

Dr. Norden will speak under the precision medicine track, "Does Precision Medicine Require Precise Data?" During his portion of the presentation, Dr. Norden will share how Cota is accelerating the path to precision medicine and oncology value-based care with providers across the country. Case studies will focus on Cota's collaboration with leading providers like Hackensack Meridian Health, Memorial Sloan Kettering Cancer Center and Baptist Health South Florida.

Cota's end-to-end provider solutions are comprised of Real-World Evidence (RWE) analytics, decision support and value-based tracking. Leveraging the patented Cota Nodal Addresstm (CNA), a precision patient classification system, and Cota Real-World Evidence (RWE), the industry's leading collection of oncology patient data, Cota's solutions improve quality and outcome in cancer care, increase oncology margins in fee-for-service and value-based arrangements and assist practices looking to transition to value-based care.

For those interested in attending Dr. Norden's presentation, please refer to the following information:

For more information or to schedule a meeting with Cota at the event, please reach out to Cota via [email protected].

About Cota 
Cota is a real-world data and analytics company that enables providers, payers and life science companies involved in diagnosing and treating complex diseases to optimize the outcomes of individual patients and lower the overall cost of the patient population served. It is powered by the patented Cota Nodal Addresstm (CNA) system, a unique digital classification methodology built by leading physicians and data scientists. The CNA is the first and only system that precisely categorizes patient factors, their diseases and intended therapies, enabling precision medicine at scale.

Cota's technology enriches medical records to create research-grade data and joins it with a suite of analysis, visualization and management tools. This enables providers, payers and life science companies to analyze, report on and research outcomes, costs, treatments and quality at any granularity and stage of the patient journey. The result is a constantly improving system that merges technology and medicine to improve the lives of patients everywhere. For more information, go to www.cotahealthcare.com 

Alessandra Nix
SHIFT Communications
[email protected]   
617.779.1860

SOURCE Cota


These press releases may also interest you

at 07:35
Agenus Inc. ("Agenus") , a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives...

at 07:34
Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An," the "Company" or the "Group," HKEX: 2318; SSE: 601318) today announced its first quarter financial results for the three months ended March 31, 2024....

at 07:31
Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announced today an option agreement for an...

at 07:30
KFSH&RC participates as a strategic partner in the Saudi American Healthcare Forum, which will take place on April 25th under the patronage of the Ministry of Health in Riyadh. This forum aims to discuss the primary healthcare challenges facing the...

at 07:30
Factor Bioscience Inc., a Cambridge-based biotechnology company focused on...

at 07:15
Encoded Therapeutics Inc., a biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today unveiled multiple pipeline programs ahead of the 27th ASGCT Annual meeting on May 7 - 11, 2024 in Baltimore, MD....



News published on and distributed by: